The law firm of Wohl & Fruchter LLP is investigating possible violations
of federal securities laws by officers and directors of GTX Inc. (GTX)
(NASDAQ: GTXI).
On August 19, 2013, GTX announced that enobosarm, its potential
treatment for muscle wasting in lung cancer patients, fell short of key
goals agreed upon with the Food and Drug Administration in two phase III
clinical trials in terms of increasing lean body mass and improving
physical function.
Upon the above news, GTX shares have declined over 60% in trading on
August 19, 2013.
Wohl & Fruchter’s investigation concerns whether GTX management
improperly concealed from investors, among other things, that past
clinical studies were deeply flawed, and thus the latest phase III
trials were likely to fail.
Persons with relevant information, and GTXI shareholders with questions
about this investigation, are invited to contact the attorney below, or
our Firm by calling 866.833.6245.
Additional information is available on our website at: http://www.wohlfruchter.com/cases/gtxi.
About Wohl & Fruchter
Wohl & Fruchter LLP represents plaintiffs in litigation arising from
fraud and other fiduciary breaches by corporate managers, as well as
other complex litigation matters. Please visit our website, www.wohlfruchter.com,
to learn more about our Firm, or contact one of our partners.
Contact:
J. Elazar Fruchter (jfruchter@wohlfruchter.com)
845.425.4658
or Toll Free 866.833.6245
Wohl & Fruchter LLP
570
Lexington Avenue
New York, NY 10022
www.wohlfruchter.com
This release may be deemed to constitute attorney advertising.
Copyright Business Wire 2013